Show simple item record

dc.contributor.authorPiperdi, B.
dc.contributor.authorAyers, M.
dc.contributor.authorPietanza, M. C.
dc.contributor.authorMok, T. S. K.
dc.contributor.authorTurna, H. Z.
dc.contributor.authorHerbst, R. S.
dc.contributor.authorLopes, G.
dc.contributor.authorKowalski, D. M.
dc.contributor.authorKasahara, K.
dc.contributor.authorWu, Y-L.
dc.contributor.authorDe Castro, G.
dc.contributor.authorCho, B. C.
dc.contributor.authorCristescu, R.
dc.contributor.authorAurora-Garg, D.
dc.contributor.authorLunceford, J.
dc.contributor.authorKobie, J.
dc.date.accessioned2021-03-03T07:38:32Z
dc.date.available2021-03-03T07:38:32Z
dc.identifier.citationHerbst R. S. , Lopes G., Kowalski D. M. , Kasahara K., Wu Y., De Castro G., Cho B. C. , Turna H. Z. , Cristescu R., Aurora-Garg D., et al., "Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in KEYNOTE-042", Immuno-Oncology Congress of the European-Society-for-Medical-Oncology (ESMO), Geneva, İsviçre, 11 - 14 Aralık 2019, cilt.30
dc.identifier.othervv_1032021
dc.identifier.otherav_1304480d-4531-4f0e-850b-9ea1040bcebc
dc.identifier.urihttp://hdl.handle.net/20.500.12627/18246
dc.language.isoeng
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectONKOLOJİ
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.titleAssociation of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in KEYNOTE-042
dc.typeBildiri
dc.contributor.departmentYale University , ,
dc.identifier.volume30
dc.contributor.firstauthorID157775


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record